Spermosens AB (publ) is listed on Spotlight Stock Market
The share is traded under the ticker SPERM and ISIN-code SE0015346424
Spermosens AB ("Spermosens" or the "Company") is pleased to announce the signing of a Memorandum of Understanding (MoU) with a well established undisclosed Japanese company to explore a commercial partnership in Japan. This MoU lays the framework and intentions for discussions regarding the distribution and commercialization of Spermosens' fertility diagnostic product, JUNO-Checked, in Japan. Potential…
Read more at CisionSpermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's second patent in the US, covering its innovative JUNO-Checked technology. The newly allowed patent, "Biosensor for Male Infertility" (Application no. 17/260,609), encompasses a broader range of…
Read more at CisionSpermosens AB (“Spermosens” or the “Company”) is pleased to announce a significant milestone in its clinical study of the next-generation fertility diagnostic product. The first couple has now been recruited for the study, which is designed to assess the diagnostic value of JUNO-Checked in male infertility. The clinical study, currently underway at the Reproductive Medicine…
Read more at CisionAktieägarna i Spermosens AB (publ), org.nr 559179–0380, (”Spermosens” eller ”Bolaget”) kallas härmed till extra bolagsstämma den 4 november 2024 kl. 16:00 på The Spark, Medicon Village, Scheeletorget 1, Lund. På den extra bolagsstämman ska ägarna ta ställning till förslag om minskning av aktiekapitalet, emission med företrädesrätt för aktieägare för att ta in ytterligare kapital, samt…
Read more at CisionNOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Today, the…
Read more at CisionSpermosens AB ("Spermosens" or the "Company") is pleased to announce the development of the next-generation of its JUNO-Checked device, a groundbreaking product designed to assess male fertility potential. Developed in collaboration with Flex Medical Solutions (FMS), this next-generation JUNO-Checked device will play a pivotal role in the upcoming clinical study, which has recently received ethical…
Read more at CisionEminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
111 46 Stockholm
Tel: +46 8 684 211 00
info@eminova.se